AbbVie Inc. $ABBV Stock: State of Alaska Department of Revenue Trims Position

by · The Cerbat Gem

State of Alaska Department of Revenue lowered its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 2.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 226,864 shares of the company’s stock after selling 5,719 shares during the period. AbbVie makes up about 0.6% of State of Alaska Department of Revenue’s holdings, making the stock its 27th biggest position. State of Alaska Department of Revenue’s holdings in AbbVie were worth $59,344,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Corient Private Wealth LP purchased a new position in AbbVie in the 2nd quarter valued at approximately $559,736,000. Legal & General Group Plc purchased a new stake in shares of AbbVie during the second quarter worth $2,905,952,000. Jupiter Topco LLC purchased a new stake in shares of AbbVie during the second quarter worth $1,560,354,000. Diamant Asset Management Inc. lifted its position in shares of AbbVie by 21,649.0% during the first quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock worth $798,456,000 after acquiring an additional 3,654,351 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new position in shares of AbbVie in the second quarter worth $817,473,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

  • Positive Sentiment: New Phase 3 data for a subcutaneous version of SKYRIZI showed meaningful clinical and endoscopic benefits in adults with moderately to severely active Crohn’s disease. The results could support regulatory review of a more convenient induction option and strengthen confidence that SKYRIZI can help offset the loss of Humira revenue. Abbvie’s Crohn’s Disease Drug Skyrizi Shows More Positive Results
  • Positive Sentiment: Analyst sentiment remains constructive. Royal Bank of Canada reaffirmed an Outperform rating, while Erste Group raised its 2027 EPS estimate to $16.34 from $16.19 and maintained a Buy rating. These views reinforce the argument that AbbVie’s newer drugs are driving sustainable post-Humira growth. Royal Bank Of Canada Reaffirms Outperform Rating for AbbVie
  • Positive Sentiment: Investors are also watching early clinical work on oral candidate ABBV-1042. The study remains at an early stage and is being conducted in healthy participants, but positive progress could add value to AbbVie’s long-term pipeline. AbbVie’s ABBV-1042 Trial Update
  • Neutral Sentiment: AbbVie’s third-quarter earnings report is scheduled for October 30. Investors will be looking for confirmation that SKYRIZI and RINVOQ growth is more than compensating for Humira’s decline; the company’s current guidance calls for third-quarter EPS of $3.84 to $3.88. AbbVie’s Q3 2026 Earnings: What to Expect
  • Neutral Sentiment: Heavy call-option activity and a broad healthcare-sector rally indicate increased investor interest, but options positioning is not a fundamental catalyst by itself. Lower Treasury yields may also be supporting defensive healthcare shares.
  • Negative Sentiment: Some investors remain concerned that AbbVie’s valuation is demanding after its rally. Comparisons with Sanofi have highlighted Sanofi’s stronger outlook and valuation, potentially limiting further upside. Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?

Insider Buying and Selling

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is currently owned by corporate insiders.

AbbVie Trading Down 0.1%

Shares of ABBV opened at $283.07 on Friday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $291.40. The company has a market cap of $500.13 billion, a PE ratio of 79.96, a price-to-earnings-growth ratio of 1.29 and a beta of 0.24. The stock has a 50-day moving average price of $261.95 and a 200-day moving average price of $238.90.

AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts predict that AbbVie Inc. will post 13.94 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is currently 195.48%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ABBV shares. Leerink Partners lifted their price target on AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Wells Fargo & Company boosted their price objective on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. Canaccord Genuity Group increased their price objective on AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Scotiabank raised their target price on AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 6th. Finally, BNP Paribas Exane raised their target price on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and an average price target of $277.18.

Read Our Latest Analysis on ABBV

AbbVie Company Profile

(Free Report)

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

Featured Stories

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).